Lung Cancer News and Research

Latest Lung Cancer News and Research

Syndax to present entinostat data against cancer at AACR meeting

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.

1 Apr 2011

Study finds continued smoking after cancer diagnosis among patients, family caregivers

Nicotine is so addictive for many people that even a cancer diagnosis doesn't help them - or their family members and caregivers - throw the cigarettes away.

31 Mar 2011

Top-line results from Biomoda's CyPath pilot study against lung cancer

Cancer diagnostics company Biomoda, Inc. today announced top-line results of its pilot study for lung cancer which shows highly significant evidence of CyPath's ability to discriminate between cancer and non-cancer groups based on sputum samples collected in a non-invasive manner.

31 Mar 2011

CCAC National Survey finds 82% of Canadians with cancer

The Colorectal Cancer Association of Canada today announced findings from the Weighing Quality of Life in Cancer National Survey showing that an alarming 82 per cent of Canadians have been touched closely by cancer and have had a close friend or family member battle cancer, or have done so themselves.

31 Mar 2011

Amgen announces top-line results from motesanib Phase 3 trial against NSCLC

Amgen, Millennium: The Takeda Oncology Company, and Takeda Pharmaceutical Company Limited today announced top-line results from the MONET1 pivotal Phase 3 trial evaluating motesanib administered in combination with paclitaxel and carboplatin in 1,090 patients with advanced non-squamous non-small cell lung cancer.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

New lung cancer drug starts human trials

A new drug for lung cancer is being tried by researchers at Oxford. The treatment, which halts the growth of cancer cells, is being trialed on those patients who have stopped responding to chemotherapy. The trial is one of the first to go ahead at the Oxford Cancer Research Centre.

29 Mar 2011

International Phase II trial to study LY2181308 efficacy in patients with lung cancer

Cancer Research UK scientists in Oxford are trialling an experimental drug to treat lung cancer patients who have stopped responding to initial chemotherapy treatment. The trial will take place at the Oxford Radcliffe Hospitals NHS Trust.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

FDA approves Medtronic's Protecta implantable defibrillators

Medtronic, Inc. today announced U.S. Food and Drug Administration approval of the Protecta portfolio of implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators.

29 Mar 2011

CPRIT awards $36.7 million grant to UT Southwestern for cancer research

The Cancer Prevention and Research Institute of Texas has awarded more than $36.7 million in new grants to investigators at UT Southwestern Medical Center to support cancer-related projects and to recruit pre-eminent cancer investigators.

29 Mar 2011

ALCMI launches new CASTLE study to treat lung cancer

The Addario Lung Cancer Medical Institute today announced the enrollment of the initial subjects into its inaugural clinical trial known as CASTLE, targeting 250 subjects over two years among academic and community medical centers in the United States.

28 Mar 2011

Molecular pharmacologist receives AACR Award for cancer research

Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel, which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas.

28 Mar 2011

UT Southwestern receives $36.7 million CPRIT grant for cancer studies

28 Mar 2011

People living at high altitudes have lower chance of dying from heart disease

In one of the most comprehensive studies of its kind, researchers at the University of Colorado School of Medicine in partnership with the Harvard School of Global Health have found that people living at higher altitudes have a lower chance of dying from ischemic heart disease and tend to live longer than others.

28 Mar 2011

Plasmid containing Sindbis replicase genes can destruct lung cancer

Alpha viruses, such as Sindbis virus, carry their genetic information on a single strand of RNA. On infection they use a protein, replicase, to produce double stranded RNA which is used as genetic material to make more viruses. However the body recognizes dsRNA as foreign, and infected cells initiate an immune response.

28 Mar 2011

Mersana commences XMT-1001 Phase 1b extension study in gastric cancer and non-small cell lung cancer

Mersana Therapeutics today announced the initiation of a Phase 1b extension study with its lead cancer product, XMT-1001, a novel DNA topoisomerase I inhibitor based on the company's Fleximer® polymer conjugate platform, in second-line gastric cancer and second-/third-line non-small cell lung cancer. The study will be carried out in 10 clinical centers in the US.

25 Mar 2011

Molecular Therapy journal publishes Mirna's new tumor suppressor miRNA mimics data

Mirna Therapeutics, Inc. announced today the publication of new results in the journal Molecular Therapy demonstrating how a neutral lipid emulsion facilitates the systemic delivery of tumor suppressor miRNA mimics and reduces the tumor burden in the lungs of mice.

24 Mar 2011

Individuals who smoke mentholated cigarettes do not develop lung cancer

Individuals who smoke mentholated cigarettes are no more likely to develop lung cancer or to die from the disease than smokers of non-mentholated cigarettes, according to a new study led by William Blot, Ph.D., professor of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tenn., and colleagues at VICC, Meharry Medical College, Nashville, and the International Epidemiology Institute, Rockville, Md.

24 Mar 2011